ArticleCurrent issues in molecular biology2025
Anticancer Effects of Combined Blue Light and Ionizing Irradiation.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
While there have been reports indicating the potential anticancer benefits of blue light irradiation and its enhanced effectiveness when combined with anticancer drugs, no studies have explored its combined use with radiation therapy. In this study, the anticancer effects of blue light irradiation alone and in combination with radiation therapy were investigated in vitro. Blue light was applied using a transilluminator (470 nm). For combination experiments, cells were exposed to X-rays 24 h after blue light irradiation. Cell viability was assessed using the trypan blue exclusion method, and protein expression was analyzed by Western blotting. Blue light irradiation suppressed the proliferation of human head and neck squamous cell carcinoma (HNSCC) cells. Furthermore, combined blue light and X-ray irradiation more effectively inhibited the proliferation of human HNSCC cells compared to either irradiation alone. Mechanistically, the irradiation of HNSCC cell line SAS with blue light suppressed the activity of extracellular signal-regulated kinase (ERK1/2), which is an important kinase that is involved in cell proliferation. Collectively, these findings suggest that blue light suppresses the proliferation of HNSCC cells, at least in part through ERK1/2 inactivation observed in SAS cells, and that its combination with radiation may represent a promising therapeutic approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.